Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients

Exclusion Criteria

• •1. PVC \< 30
• •2. Hypertensive subjects on ACE inhibitors
• •3. Pregnant or nursing mothers
• •4. Diabetic with HbA1C \> 7.5 or stigmata of end organ damage (neuropathy, retinopathy, nephropathy, cardiomyopathy)
• •5. Cholesterol \> 30 mg/dL above NCEP accepted level based on cardiac risk.
• •6. Triglycerides \> 200
• •7. Previously diagnosed obstructive coronary artery disease
• •8. Renal insufficiency (Creatinine ≥ 1.5 mg/dl)
• •9. History of cerebrovascular disease
• •10. Any chronic inflammatory disease (rheumatologic, inflammatory bowel disease, etc)
• •11. Uncontrolled Stage 2 Hypertension (160/100 mmHg), or end organ damage due to hypertension (left ventricular hypertrophy, atrial fibrillation, hematuria, renal insufficiency, prior cerebrovascular disease).
• •12. Angiotensin converting enzyme inhibitor use
• •13. Coagulopathy (INR ≥ 1.5, PTT ≥ 150% of control)
• •14. Peripheral Vascular Disease
• •15. Other chronic medical illnesses at the discretion of the investigators
• •Healthy controls are being enrolled in SCCOR Project 1, Aims 3A and 3B (IRB# 030473 and 061160) and will not be participating under this IRB number.